KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Tax Provisions (2019 - 2025)

Historic Tax Provisions for Alnylam Pharmaceuticals (ALNY) over the last 10 years, with Q4 2025 value amounting to -$25.3 million.

  • Alnylam Pharmaceuticals' Tax Provisions rose 7705.7% to -$25.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.4 million, marking a year-over-year increase of 10947.91%. This contributed to the annual value of $9.4 million for FY2025, which is 10947.91% up from last year.
  • Alnylam Pharmaceuticals' Tax Provisions amounted to -$25.3 million in Q4 2025, which was up 7705.7% from -$12.1 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Tax Provisions ranged from a high of $30.9 million in Q2 2025 and a low of -$110.2 million during Q4 2024
  • Moreover, its 5-year median value for Tax Provisions was $1.1 million (2021), whereas its average is -$3.9 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Tax Provisions skyrocketed by 1309130.43% in 2023 and then tumbled by 6031584.7% in 2024.
  • Alnylam Pharmaceuticals' Tax Provisions (Quarter) stood at -$1.8 million in 2021, then surged by 125.62% to $472000.0 in 2022, then tumbled by 61.23% to $183000.0 in 2023, then tumbled by 60315.85% to -$110.2 million in 2024, then soared by 77.06% to -$25.3 million in 2025.
  • Its Tax Provisions was -$25.3 million in Q4 2025, compared to -$12.1 million in Q3 2025 and $30.9 million in Q2 2025.